Research, press, use cases and what we are learning across neurology, immunology, respiratory and musculoskeletal programs.
In an inherited condition, every diagnosed patient points to relatives who carry the same risk and do not know it. Why that is the cheapest patient finding available, and why it rarely happens.
New obesity therapies have made adherence the constraint rather than access. What that looks like in practice, and what it takes to hold someone on a therapy for a year.
Four companies, one platform. The corporate history behind the therapeutic-area depth, for anyone doing diligence on who they are actually contracting with.
CHRINOSOR has produced seven peer-reviewed papers on biologic treatment in chronic rhinosinusitis. What a registry designed for publication looks like, and why that design decision matters.
The numbers behind the platform: countries, patients, pharmaceutical partners and the clinical networks in neurology and immunology.
A patient support program and a structured study both generate real-world evidence. They differ in what they require before you start, and in what you can do with the result.
Proprietary longitudinal cohorts serving medical, market access and commercial teams at once, with a publication pipeline built in.
One disease-specific program serving patients, clinicians and sponsors — with real-world evidence generated as a by-product rather than through a separate study.
Nothing matches that combination yet.
We are still publishing into some of these areas. Clear the filters to see everything, or try a broader combination.
Clear all filters